Earnings According to Analysts for Celgene Corporation (NASDAQ:CELG)?

Part of the data in this report is derived from Zacks Research and FactSet. They now have a $148.00 price objective on the biopharmaceutical company's stock. Looking over the CELG ranking chart, the CELG got 24 analysts recommendation as a Buy security in previous month pool in contrast with 23 analysts gave buy ratings at this month. Post opening the session at $118.5, the shares hit an intraday low of $117.28 and an intraday high of $119.31 and the price was in this range throughout the day. Jefferies Group LLC restated a "buy" rating and set a $140.00 price target on shares of Celgene in a research note on Sunday, December 18th. Leerink Swann restated a "market perform" rating and set a $139.00 price target on shares of Celgene in a research note on Wednesday, November 30th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twenty-five have issued a buy rating to the company's stock.

Celgene Corporations in-depth data and chart pattern analysis indicates that the stock price has rallied 0.51% in the past 12 Weeks, but analyzing the 6 month charts for the stock, the price continues to stay positive and keep the rally at 13.17%.

14 analysts polled by Zacks Research now have a mean target price of $143.928 on Celgene Corporation (NASDAQ:CELG). It has a past 5-day performance of -9.6 percent and trades at an average volume of 1.57M shares. The company reached its 52-Week high of $127 on Nov 9, 2016 and 52-Week low of $94.39 on Mar 17, 2016. The stock has a market capitalization of $94.74 billion, a PE ratio of 48.91 and a beta of 1.74. The share price has moved forward from its 20 days moving average, trading at a distance of 1.27% and stays 1.39% away from its 50 days moving average.

Struggling to find a way in profitable zone, the current EPS estimate trend for the next year first quarter was $1.76 while three months ago that trend was for $1.76. The company's stock has a Return on Assets (ROA) of 4.2 percent, a Return on Equity (ROE) of 8.3 percent and Return on Investment (ROI) of 5.3 percent. During the same quarter past year, the company earned $1.18 earnings per share.

The company announced its last quarter financial performance results on 01/26/2017. Equities research analysts anticipate that Celgene Co. will post $7.22 EPS for the current fiscal year.

This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was copied illegally and reposted in violation of U.S. and global copyright and trademark laws.

A number of hedge funds and other institutional investors have recently made changes to their positions in CELG. Arete Wealth Advisors LLC raised its position in shares of Celgene by 0.3% in the third quarter. Proficio Capital Partners LLC raised its position in shares of Celgene by 0.9% in the third quarter. Jolley Asset Management LLC raised its position in shares of Celgene Corporation by 2.1% in the third quarter. The share price is now 1.27 percent versus its SMA20, 1.39 percent versus its SMA50, and 7.91 percent versus its SMA200. Finally, Pittenger & Anderson Inc. increased its position in shares of Celgene by 3.8% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 588,380 shares of the biopharmaceutical company's stock valued at $58,130,000 after buying an additional 26,285 shares during the period. The company's institutional ownership is monitored at 79.8 percent.

Celgene Corp.is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.

  • Arturo Norris